Peroxisome proliferator-activated receptor α activates cyclooxygenase-2 gene transcription through bile acid transport in human colorectal cancer cell lines

  • Hiroshi Oshio
  • Takaaki Abe
  • Tohru Onogawa
  • Hideo Ohtsuka
  • Takeaki Sato
  • Takayuki Ii
  • Kouji Fukase
  • Mitsuhisa Muto
  • Yu Katayose
  • Masaya Oikawa
  • Toshiki Rikiyama
  • Shinichi Egawa
  • Michiaki Unno
Liver, Pancreas, and Biliary Tract



Evidence is accumulating that bile acids are involved in colon cancer development, but their molecular mechanisms remain unexplored. Bile acid has been reported to be associated with induction of the cyclooxygenase-2 (COX-2) gene. Because the human liver-specific organic anion transporter-2 (LST-2/OATP8/OATP1B3) is expressed in gastrointestinal cancers and might transport bile acids to the intracellular space, we studied the molecular mechanisms by which bile acids induce the transcription of COX-2, and the role of LST-2 in colonic cell lines.


Transcriptional activity of COX-2 was measured using a human COX-2 promoter-luciferase assay under various concentrations of bile acids. Electrophoresis mobility shift assays (EMSAs) for peroxisome proliferators-activated receptor (PPAR) α and cyclic AMP responsive element (CRE) were performed.


The COX-2 promoter was induced by lithocholic acid (LCA), deoxycholic acid (DCA), and chenodeoxycholic acid (CDCA). Deletion and site-directed mutation analyses showed that CRE is the responsive element for LCA. An adenovirus expression system revealed that LST-2 is responsible for induction of COX-2. By EMSA using oligonucleotides of CRE, we observed formation of a specific protein-DNA complex, which was inhibited by a specific antibody against PPARα and CRE. A PPARα-specific agonist induced transcription of COX-2.


These results indicate that COX-2 is transcriptionally activated by the addition of LCA, CDCA, and DCA and that LST-2 plays an important role by transporting bile acid to the intracellular space. Moreover, LCA-dependent COX-2 gene activation consists of a transcriptional complex including PPARα and CRE-binding protein. Thus, this induction of COX-2 may participate in carcinogenesis and progression of colorectal cancer cells.

Key words

LST-2 OATP1B3 COX-2 PPARα bile acid 


  1. 1.
    Abe T, Unno M, Onogawa T, Tokui T, Kondo TN, Nakagomi R, et al. LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology 2001;120:1689–1699.PubMedCrossRefGoogle Scholar
  2. 2.
    Abe T, Kakyo M, Tokui T, Nakagomi R, Nishio T, Nakai D, et al. Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Biol Chem 1999;274:17159–17163.PubMedCrossRefGoogle Scholar
  3. 3.
    Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD, Shapiro S. A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst 1991;83:355–358.PubMedCrossRefGoogle Scholar
  4. 4.
    Reddy BS, Rao CV, Seibert K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res 1996;56:4566–4569.PubMedGoogle Scholar
  5. 5.
    Fu SL, Wu YL, Zhang YP, Qiao MM, Chen Y. Anti-cancer effects of COX-2 inhibitors and their correlation with angiogenesis and invasion in gastric cancer. World J Gastroenterol 2004;10:1971–1974.PubMedGoogle Scholar
  6. 6.
    Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991;325:1593–1596.PubMedGoogle Scholar
  7. 7.
    Logan RF, Little J, Hawtin PG, Hardcastle JD. Effect of aspirin and non-steroidal anti-inflammatory drugs on colorectal adenomas: case-control study of subjects participating in the Nottingham faecal occult blood screening programme. BMJ 1993;307:285–289.PubMedCrossRefGoogle Scholar
  8. 8.
    Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 1994;5:138–146.PubMedCrossRefGoogle Scholar
  9. 9.
    Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and-2. J Biol Chem 1996;271:33157–33160.PubMedCrossRefGoogle Scholar
  10. 10.
    Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1991;266:12866–12872.PubMedGoogle Scholar
  11. 11.
    Jones DA, Carlton DP, McIntyre TM, Zimmerman GA, Prescott SM. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J Biol Chem 1993;268:9049–9054.PubMedGoogle Scholar
  12. 12.
    DuBois RN, Awad J, Morrow J, Roberts LJ 2nd, Bishop PR. Regulation of eicosanoid production and mitogenesis in rat intestinal epithelial cells by transforming growth factor-alpha and phorbol ester. J Clin Invest 1994;93:493–498.PubMedCrossRefGoogle Scholar
  13. 13.
    Inoue H, Yokoyama C, Hara S, Tone Y, Tanabe T. Transcriptional regulation of human prostaglandin-endoperoxide synthase-2 gene by lipopolysaccharide and phorbol ester in vascular endothelial cells. Involvement of both nuclear factor for interleukin-6 expression site and cAMP response element. J Biol Chem 1995;270:24965–249671.PubMedCrossRefGoogle Scholar
  14. 14.
    Subbaramaiah K, Telang N, Ramonetti JT, Araki R, DeVito B, Weksler BB, et al. Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res 1996;56:4424–4429.PubMedGoogle Scholar
  15. 15.
    Mestre JR, Subbaramaiah K, Sacks PG, Schantz SP, Tanabe T, Inoue H, et al. Retinoids suppress epidermal growth factor-induced transcription of cyclooxygenase-2 in human oral squamous carcinoma cells. Cancer Res 1997;57:2890–2895.PubMedGoogle Scholar
  16. 16.
    Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;107:1183–1188.PubMedGoogle Scholar
  17. 17.
    Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001;1:11–21.PubMedCrossRefGoogle Scholar
  18. 18.
    Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997;94:3336–3340.PubMedCrossRefGoogle Scholar
  19. 19.
    Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995;83:493–501.PubMedCrossRefGoogle Scholar
  20. 20.
    Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705–716.PubMedCrossRefGoogle Scholar
  21. 21.
    Masunaga R, Kohno H, Dhar DK, Ohno S, Shibakita M, Kinugasa S, et al. Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res 2000;6:4064–4068.PubMedGoogle Scholar
  22. 22.
    Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA 2002;99:13926–13931.PubMedCrossRefGoogle Scholar
  23. 23.
    Craven PA, Pfanstiel J, DeRubertis FR. Role of activation of protein kinase C in the stimulation of colonic epithelial proliferation and reactive oxygen formation by bile acids. J Clin Invest 1987;79:532–541.PubMedCrossRefGoogle Scholar
  24. 24.
    Narisawa T, Magadia NE, Weisburger JH, Wynder EL. Promoting effect of bile acids on colon carcinogenesis after intrarectal instillation of N-methyl-N′-nitro-N-nitrosoguanidine in rats. J Natl Cancer Inst 1974;53:1093–1097.PubMedGoogle Scholar
  25. 25.
    Allinger UG, Johansson GK, Gustafsson JA, Rafter JJ. Shift from a mixed to a lactovegetarian diet: influence on acidic lipids in fecal water-a potential risk factor for colon cancer. Am J Clin Nutr 1989;50:992–996.PubMedGoogle Scholar
  26. 26.
    Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, et al. Identification of a nuclear receptor for bile acids. Science 1999;284:1362–1365.PubMedCrossRefGoogle Scholar
  27. 27.
    Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA, et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 1999;284:1365–1368.PubMedCrossRefGoogle Scholar
  28. 28.
    Staudinger JL, Goodwin B, Jones SA, Hawkins-Brown D, MacKenzie KI, LaTour A, et al. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc Natl Acad Sci USA 2001;98:3369–3374.PubMedCrossRefGoogle Scholar
  29. 29.
    Makishima M, Lu TT, Xie W, Whitfield GK, Domoto H, Evans RM, et al. Vitamin D receptor as an intestinal bile acid sensor. Science 2002;296:1313–1316.PubMedCrossRefGoogle Scholar
  30. 30.
    Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature 2000;405:421–424.PubMedCrossRefGoogle Scholar
  31. 31.
    Meade EA, McIntyre TM, Zimmerman GA, Prescott SM. Peroxisome proliferators enhance cyclooxygenase-2 expression in epithelial cells. J Biol Chem 1999;274:8328–8334.PubMedCrossRefGoogle Scholar
  32. 32.
    Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: from orphan receptors to drug discovery. J Med Chem 2000;43:527–550.PubMedCrossRefGoogle Scholar
  33. 33.
    Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999;20:649–688.PubMedCrossRefGoogle Scholar
  34. 34.
    Guerre-Millo M, Gervois P, Raspe E, Madsen L, Poulain P, Derudas B, et al. Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem 2000;275:16638–16642.PubMedCrossRefGoogle Scholar
  35. 35.
    Chinetti G, Fruchart JC, Staels B. Peroxisome proliferators-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res 2000;49:497–505.PubMedCrossRefGoogle Scholar
  36. 36.
    Pineda Torra I, Claudel T, Duval C, Kosykh V, Fruchart JC, Staels B. Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor. Mol Endocrinol 2003;17:259–272.PubMedCrossRefGoogle Scholar
  37. 37.
    Zhang F, Subbaramaiah K, Altorki N, Dannenberg AJ. Dihydroxy bile acids activate the transcription of cyclooxygenase-2. J Biol Chem 1998;273:2424–2428.PubMedCrossRefGoogle Scholar
  38. 38.
    Kutchera W, Jones DA, Matsunami N, Groden J, McIntyre TM, Zimmerman GA, et al. Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Proc Natl Acad Sci USA 1996;93:4816–48120.PubMedCrossRefGoogle Scholar
  39. 39.
    von Kleist S, Chany E, Burtin P, King M, Fogh J. Immunohistology of the antigenic pattern of a continuous cell line from a human colon tumor. J Natl Cancer Inst 1975;55:555–560.Google Scholar
  40. 40.
    Knowles BB, Howe CC, Aden DP. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 1980;209:497–499.PubMedCrossRefGoogle Scholar
  41. 41.
    Dignam JD, Lebovitz RM, Roeder RG. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 1983;11:1475–14789.PubMedCrossRefGoogle Scholar
  42. 42.
    Sharp PA. RNA interference-2001. Genes Dev 2001;15:485–490.PubMedCrossRefGoogle Scholar
  43. 43.
    Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998;58:409–412.PubMedGoogle Scholar
  44. 44.
    Glinghammar B, Inoue H, Rafter JJ. Deoxycholic acid causes DNA damage in colonic cells with subsequent induction of caspases, COX-2 promoter activity and the transcription factors NF-kB and AP-1. Carcinogenesis 2002;23:839–845.PubMedCrossRefGoogle Scholar
  45. 45.
    Stadler J, Yeung KS, Furrer R, Marcon N, Himal HS, Bruce WR. Proliferative activity of rectal mucosa and soluble fecal bile acids in patients with normal colons and in patients with colonic polyps or cancer. Cancer Lett 1988;38:315–320.PubMedCrossRefGoogle Scholar
  46. 46.
    Nagengast FM, Grubben MJ, van Munster IP. Role of bile acids in colorectal carcinogenesis. Eur J Cancer 1995;31A:1067–1070.PubMedCrossRefGoogle Scholar
  47. 47.
    Ohtsuka H, Abe T, Onogawa T, Kondo N, Sato T, Oshio H, et al. Farnesoid X receptor, hepatocyte nuclear factors 1alpha and 3beta are essential for transcriptional activation of the liver-specific organic anion transporter-2 gene. J Gastroenterol 2006;41:369–377.PubMedCrossRefGoogle Scholar
  48. 48.
    Tominaga K, Higuchi K, Sasaki E, Suto R, Watanabe T, Fujiwara Y, et al. Correlation of MAP kinases with COX-2 induction differs between MKN45 and HT29 cells. Aliment Pharmacol Ther 2004;20Suppl 1:143–150.PubMedCrossRefGoogle Scholar
  49. 49.
    Rudnick DA, Perlmutter DH, Muglia LJ. Prostaglandins are required for CREB activation and cellular proliferation during liver regeneration. Proc Natl Acad Sci USA 2001;98:8885–8890.PubMedCrossRefGoogle Scholar
  50. 50.
    Ionov Y, Matsui S, Cowell JK. A role for p300/CREB binding protein genes in promoting cancer progression in colon cancer cell lines with microsatellite instability. Proc Natl Acad Sci USA 2004;101:1273–1278.PubMedCrossRefGoogle Scholar
  51. 51.
    Lu Q, Hutchins AE, Doyle CM, Lundblad JR, Kwok RP. Acetylation of cAMP-responsive element-binding protein (CREB) by CREB-binding protein enhances CREB-dependent transcription. J Biol Chem 2003;278:15727–15734.PubMedCrossRefGoogle Scholar
  52. 52.
    Arany Z, Sellers WR, Livingston DM, Eckner R. E1A-associated p300 and CREB-associated CBP belong to a conserved family of coactivators. Cell 1994;77:799–800.PubMedCrossRefGoogle Scholar
  53. 53.
    Tien ES, Davis JW, Vanden Heuvel JP. Identification of the CREB-binding protein/p300-interacting protein CITED2 as a peroxisome proliferator-activated receptor alpha coregulator. J Biol Chem 2004;279:24053–24063.PubMedCrossRefGoogle Scholar
  54. 54.
    Yoon JH, Higuchi H, Werneburg NW, Kaufmann SH, Gores GJ. Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. Gastroenterology 2002;122:985–993.PubMedCrossRefGoogle Scholar
  55. 55.
    Glinghammar B, Inoue H, Rafter JJ. Deoxycholic acid causes DNA damage in colonic cells with subsequent induction of caspases, COX-2 promoter activity and the transcription factors NF-kB and AP-1. Carcinogenesis 2002;23:839–845.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Japan 2008

Authors and Affiliations

  • Hiroshi Oshio
    • 1
  • Takaaki Abe
    • 2
    • 3
  • Tohru Onogawa
    • 1
  • Hideo Ohtsuka
    • 1
  • Takeaki Sato
    • 1
  • Takayuki Ii
    • 1
  • Kouji Fukase
    • 1
  • Mitsuhisa Muto
    • 1
  • Yu Katayose
    • 1
  • Masaya Oikawa
    • 1
  • Toshiki Rikiyama
    • 1
  • Shinichi Egawa
    • 1
  • Michiaki Unno
    • 1
  1. 1.Division of Gastroenterological Surgery, Department of SurgeryTohoku University Graduate School of Medical ScienceSendaiJapan
  2. 2.Division of Nephrology, Endocrinology, and Vascular Medicine, Department of MedicineTohoku University Graduate School of Medical ScienceSendaiJapan
  3. 3.PRESTOJapan Science and Technology Corporation (JST)TokyoJapan

Personalised recommendations